New England Journal of Medicine· 2014Q1· Clinical trial
Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
- 4,641citations
- Q1SCImago
- 2014year
Short summary
Nintedanib, an inhibitor of multiple tyrosine kinases, significantly slowed lung function decline in patients with idiopathic pulmonary fibrosis by reducing the annual rate of forced vital capacity (FVC) loss by 125.3 ml/year in one trial and 93.7 ml/year in another, compared to placebo.
AI-generated from the title and abstract; the full text is not read.
TakeawaysIn the app
Key pointsIn the app
Ask the paperIn the app
The rest is in the Pofolia app
Takeaways, key points and questions to the paper; new summaries every day for your field. Free.
Sign in on the web to openField: Pulmonary and Respiratory Medicine
Pulmonary and Respiratory MedicineMedicine